These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 24652721)
1. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Cheung N; Wong IY; Wong TY Diabetes Care; 2014 Apr; 37(4):900-5. PubMed ID: 24652721 [TBL] [Abstract][Full Text] [Related]
2. Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Simó R; Sundstrom JM; Antonetti DA Diabetes Care; 2014 Apr; 37(4):893-9. PubMed ID: 24652720 [TBL] [Abstract][Full Text] [Related]
4. Vascular Endothelial Growth Factor and Diabetic Retinal Disease. Ajlan RS; Silva PS; Sun JK Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128 [TBL] [Abstract][Full Text] [Related]
5. What have we learnt about the management of diabetic macular edema in the antivascular endothelial growth factor and corticosteroid era? Agarwal A; Sarwar S; Sepah YJ; Nguyen QD Curr Opin Ophthalmol; 2015 May; 26(3):177-83. PubMed ID: 25784111 [TBL] [Abstract][Full Text] [Related]
7. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. Giuliari GP; Guel DA; Cortez MA; Cortez RT Can J Ophthalmol; 2010 Oct; 45(5):501-8. PubMed ID: 20648074 [TBL] [Abstract][Full Text] [Related]
8. Diabetic macular edema. Lang GE Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122 [TBL] [Abstract][Full Text] [Related]
10. Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? Das A; McGuire PG; Monickaraj F Indian J Ophthalmol; 2016 Jan; 64(1):4-13. PubMed ID: 26953018 [TBL] [Abstract][Full Text] [Related]
12. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Jardeleza MS; Miller JW Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692 [TBL] [Abstract][Full Text] [Related]
13. Choroidal thickness in diabetic retinopathy: the influence of antiangiogenic therapy. Laíns I; Figueira J; Santos AR; Baltar A; Costa M; Nunes S; Farinha C; Pinto R; Henriques J; Silva R Retina; 2014 Jun; 34(6):1199-207. PubMed ID: 24280668 [TBL] [Abstract][Full Text] [Related]
14. A review of anti-VEGF agents for proliferative diabetic retinopathy. Osaadon P; Fagan XJ; Lifshitz T; Levy J Eye (Lond); 2014 May; 28(5):510-20. PubMed ID: 24525867 [TBL] [Abstract][Full Text] [Related]
15. [Role of VEGF in diseases of the retina]. Barquet LA Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():3-5. PubMed ID: 25925044 [TBL] [Abstract][Full Text] [Related]
16. Current and investigational drugs for the treatment of diabetic retinopathy. Tolentino MS; Tolentino AJ; Tolentino MJ Expert Opin Investig Drugs; 2016 Sep; 25(9):1011-22. PubMed ID: 27367620 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658 [TBL] [Abstract][Full Text] [Related]
18. Does laser still have a role in the management of retinal vascular and neovascular diseases? Shah AM; Bressler NM; Jampol LM Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309 [TBL] [Abstract][Full Text] [Related]
19. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis. Simunovic MP; Maberley DA Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553 [TBL] [Abstract][Full Text] [Related]
20. Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. Chong V Ophthalmologica; 2012; 227 Suppl 1():2-10. PubMed ID: 22517120 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]